Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Novel agents for MDS on the basis of understanding disease biology

Myelodysplastic syndromes (MDS) represent a clinically heterogeneous group of disorders with challenging unmet therapeutic needs. At the 20th Congress of the European Hematology Association (EHA), Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses emerging agents for the treatment of patients with MDS, including transforming growth factor-beta inhibitors, thrombopoietic agents and targets of mutant IDH2.